Case report of large malignant pericardial effusion in a post-surgical setting of endometrial mixed carcinoma: A description of unique cytological, histological, and immunohistochemical findings

Seiya Mizuguchi1, Akihiro Shioya1,2, Toshiyuki Sasagawa3, Sumire Yamada3, Kenichi Mizutani1,2, Nozomu Kurose1,2 and Sohsuke Yamada1,2

Abstract
Appearance of endometrial carcinoma in pericardial effusion is extremely rare. Its major etiological factors include lung cancer, breast cancer, lymphoma, and leukemia. We herein report a case of a large malignant pericardial effusion 7 years after surgery for endometrial carcinoma. A 66-year-old woman who underwent modified radical hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection for endometrial carcinoma 7 years ago and who had self-interrupted subsequent chemotherapy was presented with vertigo and vomiting. Chest computed tomography revealed pericardial effusion. Cytological examination diagnosed it as adenocarcinoma with psammoma bodies and mitoses. Immunohistochemistry analysis revealed that adenocarcinoma cells were positive for p53, p16, and insulin-like growth factor II mRNA-binding protein-3, but negative for estrogen receptor. Adenocarcinoma cells in pericardial effusion were morphologically and immunohistochemically similar to the serous carcinoma component of the surgical specimen. The appearance of psammoma bodies in cytological examination triggered the diagnosis.

Keywords
Mixed carcinoma, pericardial effusion, cytology, endometrium, psammoma body

Date received: 22 July 2019; accepted: 10 May 2020

Background
Malignant disease of the pericardium, either primary or metastatic, is known to be the cause of pericardiac effusion.1,2 The major etiological factors of malignant pericardial effusion include lung cancer, breast cancer, lymphoma, and leukemia, whereas cardiac metastasis from gynecological malignancies is known to be extremely rare. As far as the authors are aware, endometrial mixed carcinoma has never been reported to cause malignant pericardial effusion. Following a diagnosis of endometrioid carcinoma in one of our patients, endometrial cancer surgery was performed. However, 7 years later, a large pericardial effusion occurred, and surgical specimens were reexamined due to detection of serous adenocarcinoma components following cytological examination of the pericardial effusion. This report presents this partial mixed serous adenocarcinoma case.

Case
A 66-year-old woman who underwent modified radical hysterectomy, bilateral salpingo-oophorectomy and lymph node dissection for endometrial carcinoma 7 years ago, and who had self-interrupted subsequent chemotherapy (docetaxel and carboplatin for four courses) was presented with vertigo...
and vomiting. At the time the patient was consulted, her consciousness was clear, temperature was 37.2°C, respiratory rate was 24 breaths per min, heart rate was 101 bpm, blood pressure was 114/82 mm Hg, and oxygen saturation was 94% on room air. Echocardiography showed a large accumulation of pericardial effusion, but cardiac wall motion was maintained. Chest computed tomography revealed a large pericardial effusion (Figure 1(a), left) and a mass measuring 8 cm in size from the pericardium to the liver surface (Figure 1(a), right).

Accordingly, pericardiocentesis was performed for treatment. As metastasis of endometrial carcinoma was suspected, we performed cytological examination of the pericardial effusion. Results revealed the presence of many three-dimensional papillary and solid clusters of atypical glandular cells in a background of erythrocytes. Atypical glandular cells were observed to exhibit a foamy cytoplasm, enlarged nuclei, fine chromatin, and distinct nucleoli (Figure 1(b)). Psammoma bodies (Figure 1(c), left) and mitoses (Figure 1(c), right) were also partly observed.

Immunohistochemistry of a cell block of the pericardial effusion showed that adenocarcinoma cells were positive for tumor protein p53 (p53), cyclin-dependent kinase inhibitor 2A (CDKN2A, also known as p16), and insulin-like growth factor II mRNA-binding protein-3 (IMP-3), but negative for estrogen receptor (ER; Figure 2, top line). A surgical specimen from the endometrial carcinoma dissected 7 years earlier had been diagnosed as moderately differentiated endometrioid adenocarcinoma (G2 > G1, pT3pN1cMX, pStageIIIC) (left) (HE staining; original magnification, 40×). On retrospective evaluation of this specimen, a partly included papillary serous carcinoma-like component was identified (right) (HE staining; original magnification, 100×).
pericardial effusion. After relapse was confirmed through cytodiagnosis, a single dose of 500 mg carboplatin and 260 mg paclitaxel was administered to the patient. However, 20 days after administration, the patient suffered decreased blood pressure, labored breathing, and pleural fluid accumulation. The overall condition of the patient gradually worsened thereafter, and she passed away 30 days after administration. Clinically, the cause of death was considered to be carcinomatous pericarditis, but no autopsy was performed following the wishes of the family.

Discussion

Teresa has reported that lung, breast, and hematologic cancers account for 38%, 23%, and 18% of cases of malignant pericardial effusion, respectively. The remaining 21% of cases of effusion have been shown to be secondary to adenocarcinoma of unknown primary source, thymoma, ovarian carcinoma, mesothelioma, testicular carcinoma, osteogenic sarcoma, and gastrointestinal tract and genitourinary tract malignancies. The appearance of endometrial carcinoma in pericardial effusion is known to be extremely rare.

Previous cases of malignant pericardial effusion have occurred after hysterectomy for endometrial carcinoma, such as serous carcinoma, clear cell carcinoma, poorly differentiated endometrial adenocarcinoma, and carcinosarcoma. Most of these cases showed other sites of metastasis, including the pericardium. However, there was no other recurrence, except for pericardium in a single case. The long recurrence interval was a defining characteristic of that case, which was similar to our own case. To our knowledge, none of the previous case reports mentioned the reasons behind the accumulation of pericardial fluid, but we believe that the pericardial effusion in our case was due to the pericardial infiltration of the metastatic mass from the pericardium to the liver surface.

In the World Health Organization (WHO) classification of Tumors of Female Reproductive Organs, mixed carcinoma is defined as a mixed endometrial carcinoma composed of two or more different histological types of...
endometrial carcinoma, at least one of which belongs to the type II category. In addition, the behavior of these tumors has been reported to correlate with the highest-grade component, and a serous component of as little as 5% in a mixed carcinoma might adversely influence the outcome. According to Quddus et al., in clinicopathological examinations of stage I mixed-type carcinomas with serous carcinomas or clear cell carcinomas as a minor component, survival time was observed to be shorter for patients with mixed-type carcinoma than for those with pure endometrioid carcinoma. In the research of Li et al. as well, when mixed-type endometrioid carcinoma contained serous components, prognosis was found to be significantly worse. As such, the presence or absence of serous carcinoma has been considered as an important factor in predicting prognosis. Li et al. divided relapse cases into groups based on whether the relapse occurred in the pelvic cavity or distant sites and investigated the incidence of pure endometrioid carcinoma, serous carcinoma, and mixed-type carcinoma, but there was no significant difference observed in the observed frequency of the relapse site based on tissue type.

In our case, most of the tumors were endometrioid carcinoma, but cytological examination of the pericardial effusion with immunohistochemistry revealed the presence of serous carcinoma components. A retrospective evaluation of the surgical specimen revealed partial serous carcinoma-like components, which were considered to have metastasized to the pericardium. Under the current definition, our case might be considered as a case of mixed carcinoma. Of note, the cytological examination in our patient led to the diagnosis of endometrial mixed carcinoma. If serous carcinoma components had been discovered upon closer examination at a point in time in the past when diagnostics on samples from primary endometrial cancer surgery were being conducted, this would have enabled a more accurate prognosis of the main tumor to be expressed to the patient. Accordingly, this might have prevented the patient from deciding to terminate her treatment from the perspective of poor prognosis. Therefore, it is made apparent that if there are suspicions of serous components within an endometrioid carcinoma, additional immunohistochemical examinations should be performed.

In the present patient, adenocarcinoma cells were observed to appear with psammoma bodies in the pericardial effusion. Although papillary thyroid carcinoma is a differential diagnosis for a malignant tumor with psammoma bodies, this entity was excluded based on clinical information and cytomorphology. Adenocarcinoma cells in the pericardial effusion were shown to be morphologically and immunohistochemically similar to the serous carcinoma-like components of the surgical specimen. These results supported the notion that serous carcinoma-like components could appear in pericardial effusion.

Conclusion
We encountered a case in which cytological examination of pericardial effusion led to the diagnosis of endometrial mixed carcinoma. The appearance of psammoma bodies triggered the diagnosis. The detailed examination of the mixed carcinoma components that defined the prognosis was considered important.

Acknowledgements
The authors would like to thank Editage (www.editage.com) for English language editing services. This paper is based on a presentation delivered at the 35th Annual Meeting of the Ishikawa Prefecture Society of Clinical Cytology in 2019. They also thank all members of our department.

Author contributions
S.M., A.S., and Su.Y. participated in the conception of the idea and writing of the manuscript. S.M., A.S., T.S., Su.Y., K.M., N.K., and So.Y. performed the clinical investigation and pathological/immunohistochemical examination. All authors have read and approved the final manuscript.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval
Our institution does not require ethical approval for reporting individual cases or case series.

Informed consent
Written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article.

Consent for publication
Written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article.

Availability of data and materials
The data set supporting the findings and conclusions of this case report is included within the article.

ORCID iDs
Seiya Mizuguchi https://orcid.org/0000-0002-0636-9058
Akihiro Shioya https://orcid.org/0000-0002-1863-5368
Kenichi Mizutani https://orcid.org/0000-0003-2742-5693
Nozomu Kurose https://orcid.org/0000-0003-3626-4633
Sohsuke Yamada https://orcid.org/0000-0003-2662-0024

References
1. Martínez-Girón R, Pantanowitz L, Martínez-Torre S, et al. Sudden cardiac death due to primary malignant pericardial
mesothelioma: brief report and literature review. Respir Med Case Rep 2019; 26: 185–188.
2. Liu G, Zhang Q, Li Z, et al. Endometrial carcinoma complicated by malignant pericardial effusion: a case report on the therapeutic regimen. Medicine (Baltimore) 2019; 98(42): e17584.
3. Tsang TS, Seward JB, Barnes ME, et al. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clin Proc 2000; 75(3): 248–253.
4. Hayashi Y, Iwasaka T, Hachisuga T, et al. Malignant pericardial effusion in endometrial adenocarcinoma. Gynecol Oncol 1988; 29: 234–239.
5. Ramirez PT, Ramondetta LM, Burke TW, et al. Metastatic uterine papillary serous carcinoma to the pericardium. Gynecol Oncol 2001; 83(1): 135–137.
6. Kogan J, Golzman B, Turkot S, et al. Malignant pericardial effusion and cardiac tamponade as a late complication of endometrial carcinoma. Eur J Intern Med 2004; 15(5): 318–320.
7. Kheterpal P, Singh M, Mondul A, et al. Malignant pericardial effusion and cardiac tamponade in endometrial adenocarcinoma. Gynecol Oncol 2001; 83(1): 143–145.
8. Santala M, Puistola U and Kauppila A. Endometrial adenocarcinoma complicated by malignant pericardial effusion. Gynecol Oncol 1995; 56(3): 444–445.
9. Shimizu S, Yajima M, Yoshii A, et al. Malignant pericardial effusion and cardiac tamponade originating from uterine carcinosarcoma. Arch Gynecol Obstet 2009; 279(3): 373–375.
10. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC press 2014, p.132.
11. Quddus MR, Sung CJ, Zhang C, et al. Minor serous and clear cell components adversely affect prognosis in “mixed-type” endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci 2010; 17(7): 673–678.
12. Li W, Li L, Wu M, et al. The prognosis of stage IA mixed endometrial carcinoma. Am J Clin Pathol 2019; 152: 616–624.